Toxicology Report

Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -

Selenious Acid

What is Selenious Acid?

CAS No: 7783-00-8

Selenious Acid is an acid compound whose pharmaceutical applications span formulation excipient use, synthetic reagent functions, and in some cases direct therapeutic activity. The pKₐ of Selenious Acid determines the ionisation equilibrium relevant to its GI absorption, renal clearance, and tissue distribution when present as an impurity or excipient component at trace levels. Occupational exposure to Selenious Acid in manufacturing environments is primarily assessed for irritant corrosive effects on the respiratory tract and skin, with OEL values reflecting the concentration producing no adverse local tissue effects in the most sensitive exposure studies.

The intraspecies uncertainty factor F2 for Selenious Acid covers the range of pharmacokinetic and pharmacodynamic variability within the human population, ensuring the derived PDE is protective for sensitive subgroups including paediatric patients with immature CYP450 activity, elderly patients with reduced hepatic and renal clearance, patients wit

To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).

Request Your Assessment

Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.

View Inquiry List →
What's included:
Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
9,000+
Toxicological & Exposure
Assessment Reports Delivered
70+
Subject Matter Experts
across global operations
12
In-House Ex-Agency
Toxicologists
3
Certification Bodies:
ERT · UKRT · DABT

Assessment Methodology

Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.

EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)

Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.

PIC/S – Shared Facilities and Contamination Control Guidance

Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.

ICH Q9 – Quality Risk Management

Provides a structured methodology for risk identification, assessment, control, communication, and review.

ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)

Applied for compounds with potential mutagenic or genotoxic concerns.

Risk-Based Toxicological Assessment

Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.

Weight-of-Evidence (WoE) Approach

Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.

Report Preparation Process

Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.

01

Comprehensive Data Review

Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.

02

Scientific Evaluation

Identification of critical endpoints and selection of appropriate exposure limits.

03

PDE / HBEL Derivation

Transparent and scientifically justified calculations aligned with global toxicological principles.

04

Ex-Agency Expert Review (Our Differentiator)

Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.

05

Final Report Delivery

Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).

Why Masuu Global?

Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.

✓

Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.

✓

Inspection-ready reports — scientifically defensible and audit-prepared from day one.

✓

Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).

✓

Practical implementation recommendations that translate science into actionable contamination control.

✓

Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.

✓

Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.

Ready to request your assessment?

Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.

Frequently Asked Questions

Selenious Acid is a named chemical or pharmaceutical-related substance. Its precise classification, grade, and intended use should be confirmed from the applicable technical documentation rather than inferred from the name alone. A toxicological assessment should evaluate reliable evidence for the specific material and consider its manufacturing and handling context, with assumptions and data gaps clearly documented.

A PDE or ADE sets a health-based limit on daily exposure to (2R,4S)-2-Ethyl-6-(Trifluoromethyl)-1,2,3,4-Tetrahydroquinoline-4-Amine from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.

A PDE for Selenious Acid is generally derived for a defined exposure context and should not automatically be assumed to apply identically to every route. Oral, inhalation, dermal, and other routes can involve different absorption and local effects. The assessor should review the intended use, route-specific evidence, and relevant guidance, documenting whether adjustments or separate considerations are needed for the situation being evaluated.

Potential carryover of Selenious Acid is evaluated within a documented contamination-control and cleaning-validation assessment. The review can consider the manufacturing sequence, shared equipment, batch and product context, residue locations, cleaning processes, and the analytical method's suitability. A health-based exposure limit may inform acceptance criteria, but the final approach should also address process capability and applicable quality requirements.

The assessment of Selenious Acid should consider reliable evidence for the specific substance, including repeat-dose toxicity, genotoxicity, reproductive and developmental endpoints, and pharmacological effects where relevant. The evaluator should identify the critical effect, assess study quality and relevance, and document data gaps. Conclusions should remain proportionate to the evidence rather than assume unsupported hazards or safety.

An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.

An OEB places (2R,4S)-2-Ethyl-6-(Trifluoromethyl)-1,2,3,4-Tetrahydroquinoline-4-Amine in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.

Where Selenious Acid has relevant pharmacological activity, that activity may inform the selection of critical effects and interpretation of dose-response evidence. The evaluator should consider the mechanism, potency, target organs, and relevance of the available non-clinical or clinical information, where appropriate. A PDE should be based on the complete weight of evidence and a documented rationale, not on therapeutic dose information alone.

Uncertainty factors for Selenious Acid are selected according to the nature and quality of the available evidence, including differences between study subjects and humans, duration of exposure, and the severity or relevance of the critical effect. The rationale for each factor should be transparent and scientifically justified. Factors should not be chosen mechanically; the overall approach should reflect the evidence and remaining uncertainties.

The assessment for Selenious Acid should be reviewed when meaningful new toxicological data become available, the material's intended use or exposure route changes, manufacturing or handling conditions change, or relevant guidance is updated. A review may also be appropriate if new evidence changes the understanding of a critical effect. The reason for review and any resulting revisions should be documented through the applicable quality system.

Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.

Use the Request Your Assessment option on this page and add (2R,4S)-2-Ethyl-6-(Trifluoromethyl)-1,2,3,4-Tetrahydroquinoline-4-Amine to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.

Book a Demo